PRAX (Praxis Corp) Price-to-Projected Revenue Ratio
The development of unique targeted epilepsy drugs allows Praxis Precision Medicines (PRAX) to command premium pricing. The company's expected P/S ratio confirms market expectations, with the latest mark standing at 1210.80. Stable management is precisely executing R&D plans, although geopolitical tensions and patent complexities could hinder global expansion and raw material logistics.
Analytical breakdowns for Praxis Precision Medicines
- market price and analyst price targets:
- business market valuation indicators:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Praxis Precision Medicines|PRAX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Praxis Precision Medicines Inc|PRAX - Company Total Debt Obligations|Debts to Book Capitalization Praxis Medicines|PRAX - Long-Term Debt Volume|Company Short-Term Debt Praxis Precision Medicines|Quick Liquidity praxismedicines.com
- financial results and valuation multiples details:
PRAX - Company Profit|Future Profit Praxis Precision Medicines|PRAX - Company Value to Net Income|Future Price to Earnings praxismedicines.com|PRAX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Praxis Corp|PRAX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Praxis Precision Medicines|PRAX - Earnings per share for the last 12 months|Quarterly EPS earnings growth praxismedicines.com|PRAX - Expected net earnings per share growth this year|Earnings growth forecast for next year Praxis Precision Medicines
- revenue and sales details:
Comprehensive company analysis:Praxis Corp PRAX
Portfolio managers evaluate the operating model of Praxis Precision Medicines (PRAX) through the lens of future cash flows. This indicator measures the market value of one dollar of expected revenue, neutralizing the time lag between quarterly reports. By analyzing the forward P/S ratio, investors can see the current overvaluation of the potential for CNS therapies and genetic developments. The stability of this metric confirms the fundamental resilience of the company's scientific foundation in treating psychoses.
Analysis of competing companies
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|AVXL: Forward P/S Multiple|CBLL (ceribell.com) - Price-to-Projected Revenue Ratio|PRTA (Prothena Corporation) - Forward P/S Multiple|Forward Price-to-Revenue Multiple alector.com (ALEC)|Price-to-Projected Revenue Ratio Annexon, Inc. (ANNX)|OMER - Market Cap to Future Revenue Ratio|Forward P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Market Cap to Future Revenue Ratio|Voyager Therapeutics Inc - Forward P/S Multiple|Neumora (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
